Runderweg 6 8219 PK Lelystad
InnoSer, a contract research laboratory specialized in genetically altered (GA) research models under high quality and standardised lab conditions.
InnoSer was founded in 2011 to accommodate the increasing demand for professional expertise and infrastructure of academic research institutes in the Netherlands and other European countries . InnoSer offers services for in-vivo and in-vitro bioresearch which includes colony management, pathology, sanitation, cryopreservation and generation of GA research models.
All our services are open to public and private enterprises and individual investigators.
InnoSer’s unique business concept is based on the principle that the intellectual property of the GA animals and ownership remains with the scientist. InnoSer offers ‘hotel services’ at competitive prices made possible by economy of scale. InnoSer’s operation is based on the 4Rs concept – Replacement, Reduction, Refinement and Responsible animal experimentation. Corporate Societal Responsibility (CSR) is the guiding principle of our business model.
InnoSer combines experience in the commercial operations of a large state-of-the-art service facility for GA (Genetically Altered) models with expert knowledge and expertise in laboratory animal science and the life sciences. We are ideally suited to provide high quality GA services and to facilitate human health research whilst optimal animal health and wellbeing is also part of our company culture.
- phenotyping – pathology
- Genetically Engineered (Mice) Models
- repository (embryo and sperm library)
Expertise and Track Record
The mouse has proven to be an excellent system for studying the role of genetic and environmental factors in cancer, immunology etc. in an intact organism. In the last decade, disease modeling in genetically engineered mice has become increasingly important and has resulted in important breakthroughs in our understanding of the molecular basis of many human diseased. The Netherlands has a prominent position in the development and use of genetically engineered mouse models (GEMMs) and has a leading position in Europe in this area. However, to maintain and further expand this prominent role, a critical investment in new technologies is required for the following reasons:
Modeling complex diseases such as cancer, Alzheimer, diabetic in mice requires GEMMs carrying multiple defined genomic alterations. Introducing such modifications by conventional breeding is inefficient because it is time consuming and requires large numbers of mice.
Recent advances in embryonic stem cell (ESC) technology permit efficient derivation of ESC lines from established GEMMs. These GEMM-ESCs are of such high quality that they can be used for the production of experimental cohorts of high-grade chimeras carrying all the desired genetic modifications. This technology permits the creation of an archive of (compound) mutant GEMM-ESC lines, rather than live mice, thereby effectively reducing the number of animals needed for breeding and maintaining GEMM lines. The cumulative GEMM-ESC resource not only allows investigators to quickly generate mice with these modifications, it also serves as a starting point for introducing additional modifications, thus permitting the swift generation of mice with complex genotypes tailored to the needs of cancer and aging related research.
We believe that by working together in a public – private collaboration we can maintain critical basic load for an efficient Tg operation and stay highly innovative and effective at the same time. In the IMPAct concortium the NKI is transferring unique knowledge as described above to Innoser. InnoSer will make the GEMM-ESC technique available for the Dutch and European market. This is unique for the Netherlands and Europe.
MRA Clustersubsidie Noord Holland, project IMPAct, InnoSer was the secretary of the IMPAct consortium with the partners NKI, AMC, UvA/SILS, KNAW Nederlands Herseninstituut, VUmc, Sylics, UMC Utrecht and University Utrecht. The project did receive the grant of 500k€ for setting up a shared GEMM facility.
Attached you will find the project description.